Navigating the Updated Anaphylaxis Parameters

<p/> <p>Anaphylaxis, an acute and potentially lethal multi-system clinical syndrome resulting from the sudden, systemic degranulation of mast cells and basophils, occurs in a variety of clinical scenarios and is almost unavoidable inmedical practice. Healthcare professionalsmust be able to recognize its features, treat an episode promptly and appropriately, and be able to provide recommendations to prevent future episodes. Epinephrine, administered immediately, is the drug of choice for acute anaphylaxis. The discussion provides an overview of one set of evidence-based and consensus parameters for the diagnosis and management of anaphylaxis.</p

Managing idiopathic short stature: role of somatropin (rDNA origin) for injection

Idiopathic short stature (ISS) is a term that describes short stature in children who do not have growth hormone (GH) deficiency and in whom the etiology of the short stature is not identified. Between 1985 and 2000, more than 40 studies were published regarding GH therapy for ISS. Only 12 of these had data to adult height, of which only 4 were controlled studies. A subsequent placebo-controlled study that followed subjects to adult height indicated that there was a gain of 3.7–7.5 cm in height with GH treatment. In 2003, the US Federal Drug Administration (FDA) approved GH for treatment of short stature. Even before FDA approval, patients with ISS made up about 20% of patients in GH databases, which is largely unchanged since FDA approval. There remains some controversy as to whether GH should be used to treat ISS. This controversy centers on the fact that there has been no definitive demonstration that short stature results in a disadvantage or problems with psychological adjustment, and thus, no demonstration that GH therapy results in improvement in quality of life

Emerging options in growth hormone therapy: an update

Growth hormone (GH) was first used to treat a patient in 1958. For the next 25 years it was available only from cadaver sources, which was of concern because of safety considerations and short supply. In 1985, GH produced by recombinant DNA techniques became available, expanding its possible uses. Since that time there have been three indications approved by the US Food and Drug Administration (FDA) for GH-deficiency states and nine indications approved for non-GH-deficiency states. In 2003 the FDA approved GH for use in idiopathic short stature (ISS), which may indirectly cover other diagnoses that have short stature as a feature. However, coverage for GH therapy is usually more reliably obtainable for a specific indication, rather than the ISS indication. Possible future uses for GH therapy could include the treatment of syndromes such as Russell–Silver syndrome or chondrodystrophy. Other non-short-stature indications could include wound healing and burns. Other uses that have been poorly studied include aging and physical performance, in spite of the interest already shown by elite athletes in using GH. The safety profile of GH developed over the past 25 years has shown it to be a very safe hormone with few adverse events associated with it. The challenge for the future is to follow these patients into adulthood to determine whether GH therapy poses any long-term risks

The Evaluation and Followup of Children Referred to Pediatric Endocrinologists for Short Stature

Objective. To characterize the pediatric endocrinologists' evaluation and followup of short-statured patients. Study Design. Observational study of 21,548 short-statured children (April 1996 to December 1999). Baseline demographics, laboratory testing, height standard deviation score (SDS), target height, and height relative to target height were analyzed at initial and return visits with the specialist. Patients were scheduled for at least one return visit and no recombinant human growth hormone therapy was administered. Results. Mean patient age was 8.6 years with a mean height SDS of −2.1. Patients were predominantly male (69%), prepubertal (73%), and white (76%). Few screening tests were obtained during initial evaluation. Nearly 40% of children did not return for their second scheduled visit. The follow-up rate was unrelated to demographics or degree of short stature. Conclusions. Low return rates limit specialists' ability to monitor growth or obtain laboratory testing over time. Further studies are needed to determine which tests should be obtained at the initial clinic visit as well as the basis for the low return rate in this group of children

Ocean Bottom Seismometer Augmentation of the Philippine Sea Experiment (OBSAPS) cruise report

The Ocean Bottom Seismometer Augmentation to the Philippine Sea Experiment (OBSAPS, April-May, 2011, R/V Revelle) addresses the coherence and depth dependence of deep-water ambient noise and signals. During the 2004 NPAL Experiment in the North Pacific Ocean, in addition to predicted ocean acoustic arrivals and deep shadow zone arrivals, we observed "deep seafloor arrivals" that were dominant on the seafloor Ocean Bottom Seismometer (OBS) (at about 5000m depth) but were absent or very weak on the Distributed Vertical Line Array (DVLA) (above 4250m depth). These "deep seafloor arrivals" (DSFA) are a new class of arrivals in ocean acoustics possibly associated with seafloor interface waves. The OBSAPS cruise had three major research goals: a) identification and analysis of DSFAs occurring at short (1/2CZ) ranges in the 50 to 400Hz band, b) analysis of deep sea ambient noise in the band 0.03 to 80Hz, and c) analysis of the frequency dependence of BR and SRBR paths as a function of frequency. On OBSAPS we deployed a fifteen element VLA from 12 to 852m above the seafloor, four short-period OBSs and two long-period OBSs and carried out an 11.5day transmission program using a J15-3 acoustic source.Funding was provided by the Office of Naval Research under Contract Nos. N00014-10-1-0994 and N00014-10-1-0987

Preliminary acoustic and oceanographic observations from the ASIAEX 2001 South China Sea Experiment

The Asian Seas International Experiment (ASIAEX) was a very successful scientific collaboration between the United States of America (USA), the People’s Republic of China (PRC), Taiwan (ROC), the Republic of Korea (ROK), Japan, Russia, and Singapore. Preliminary field experiments associated with ASIAEX began in spring of 2000. The main experiments were performed in April-August, 2001. The scientific plan called for two major acoustics experiments, the first a bottom interaction experiment in the East China Sea (ECS) and the second a volume interaction experiment in the South China Sea (SCS). In addition to the acoustics efforts, there were also extremely strong physical oceanography and geology and geophysics components to the experiments. This report will concentrate on describing the moored component of the South China Sea portion of ASIAEX 2001 performed from the Taiwan Fisheries research vessel FR1 (Fisheries Researcher 1). Information on the environmental moorings deployed from the Taiwanese oceanographic research vessel OR1 (Oceanographic Researcher 1) will also be listed here for completeness, so that the reader can pursue later analyses of the data. This report does not pursue any data analyses per se.Funding was provided by the Office of Naval Research under Grant Numbers N00014-01-1-0772, N00014-98-1-0413 and N00014-00-1-0206

Acoustic and oceanographic observations and configuration information for the WHOI moorings from the SW06 experiment

This document describes data, sensors, and other useful information pertaining to the moorings that were deployed from the R/V Knorr from July 24th to August 4th, 2006 in support of the SW06 experiment. The SW06 experiment was a large, multi-disciplinary effort performed 100 miles east of the New Jersey coast. A total of 62 acoustic and oceanographic moorings were deployed and recovered. The moorings were deployed in a “T” geometry to create an along-shelf path along the 80 meter isobath and an across-shelf path starting at 600 meters depth and going shoreward to a depth of 60 meters. A cluster of moorings was placed at the intersection of the two paths to create a dense sensor-populated area to measure a 3-dimensional physical oceanography. Environmental moorings were deployed along both along-shelf and across-shelf paths to measure the physical oceanography along those paths. Moorings with acoustic sources were placed at the outer ends of the “T” to propagate various signals along these paths. Five single hydrophone receivers were positioned on the across shelf path and a vertical and horizontal hydrophone array was positioned at the intersection of the “T” to get receptions from all the acoustics assets that were used during SW06.Funding was provided by the Office of Naval Research under Contract No. N00014-04-1014

Genetic and phenotypic characterization of African goat populations to prioritize conservation and production efforts for small-holder farmers in sub-Saharan Africa

Food production systems in Africa depend heavily on the use of locally adapted animals. Goats are critical to small-holder farmers being easier to acquire, maintain, and act as scavengers in sparse pasture. Indigenous goats have undergone generations of adaptation and genetic isolation that have led to great phenotypic variation. These indigenous goats serve as a genetic reservoir for the identification of genes important to environmental adaptation, disease resistance, and improved productivity under local conditions. The immediate goal is to characterize African goat populations to prioritize conservation and production efforts and to develop genomic tools for use in selective breeding programs. We have established a standardized phenotypic scoring system to characterize goats including geographical information data, body measurements, photo characterization, and DNA. To date, 2,443 goats from 12 countries, representing 46 breeds have been sampled. Using the 50K goat beadchip, we report parameters of population structure of 620 African goats